Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

1-25 of 985 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

IDH1/2 Mutations in Cancer: Unifying Insights and Unlocking Therapeutic Potential for Chondrosarcoma.
Deshmukh S, Kelly C, Tinoco G
Target Oncol, 15 Nov 2024
Cited by: 0 articles | PMID: 39546097
Add to export list Review
Adjuvant Immune Checkpoint Inhibitors for Muscle-Invasive Urothelial Carcinoma: An Updated Systematic Review, Meta-analysis, and Network Meta-analysis.
Yanagisawa T, Mori K, Matsukawa A, Kawada T, Katayama S, Laukhtina E, Rajwa P, Quhal F, Pradere B, Fukuokaya W, Iwatani K, Afferi L, Marcq G, Mertens LS, Gallioli A, Tully KH, Caño-Velasco J, Subiela JD, Abu-Ghanem Y, [...] European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)
Target Oncol, 13 Nov 2024
Cited by: 0 articles | PMID: 39535690
Add to export list Review
Delayed Separation of Kaplan-Meier Curves is Commonly Observed in Studies of Advanced/Metastatic Solid Tumors Treated with Anti-PD-(L)1 Therapy: Systematic Review and Meta-Analysis.
Oh DY, Rokutanda N, Żotkiewicz M, He P, Stocks J, Johnson ML
Target Oncol, 10 Nov 2024
Cited by: 0 articles | PMID: 39522075
Add to export list Review
Post-Metastasis Survival of Patients with High-Risk Localized and Locally Advanced Prostate Cancer Undergoing Primary Treatment in the United States: A Retrospective Study.
Freedland SJ, Fernandes L, De Solda F, Buyukkaramikli N, Mundle SD, McCarthy SA, Labson D, Yang L, Pan F, Mir C
Target Oncol, 10 Nov 2024
Cited by: 0 articles | PMID: 39522076
Add to export list
Optimal Duration of Consolidation Durvalumab Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: A Multi-institutional Retrospective Study.
Doi H, Matsuo Y, Kishi N, Ogura M, Mitsuyoshi T, Ueki N, Ueki K, Fujii K, Sakamoto M, Atsuta T, Katagiri T, Sakamoto T, Narabayashi M, Ohtsu S, Fujishiro S, Kishi T, Mizowaki T, Kyoto Radiation Oncology Study Group (KROSG)
Target Oncol, 07 Nov 2024
Cited by: 0 articles | PMID: 39511126
Add to export list
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial.
Hamilton EP, Falchook GS, Wang JS, Fu S, Oza AM, Imedio ER, Kumar S, Ottesen L, Mugundu GM, de Bruin EC, O'Connor MJ, Jones SF, Spigel DR, Li BT
Target Oncol, 19(6):879-892, 01 Nov 2024
Cited by: 0 articles | PMID: 39487373 | PMCID: PMC11557630
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Risk and Benefit for Basket Trials in Oncology: A Systematic Review and Meta-Analysis.
Klas K, Strzebonska K, Zaborowska L, Krawczyk T, Włodarczyk A, Bąk-Kuchejda U, Polak M, Van Wambeke S, Waligora M
Target Oncol, 26 Oct 2024
Cited by: 0 articles | PMID: 39455508
Add to export list Review
Durvalumab Following Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Differences in Survival Based on Age and Post-Progression Systemic Therapy.
Ksienski D, Truong PT, Bone JN, Egli S, Clarkson M, Patterson T, Lesperance M, Lakkunarajah S
Target Oncol, 04 Nov 2024
Cited by: 0 articles | PMID: 39489887
Add to export list
Correction: Ivosidenib: A Review in Advanced Cholangiocarcinoma.
Frampton JE
Target Oncol, 22 Oct 2024
Cited by: 0 articles | PMID: 39438389
Add to export list
Pancreatitis in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Koseki M, Nishimura Y, Elias E, Estaris J, Chesta F, Takaoka K, Shao T, Horita N, Fujiwara Y
Target Oncol, 19(6):867-877, 11 Oct 2024
Cited by: 0 articles | PMID: 39392549
Add to export list Review
Taiwan Nationwide Study of First-Line ALK-TKI Therapy in ALK-Positive Lung Adenocarcinoma.
Zheng ZR, Wu JJ, Chiang CJ, Chen TI, Chen KC, Chu CH, Lin SY, Yu SL, Lee WC, Liu TW, Chang GC
Target Oncol, 19(6):941-955, 11 Oct 2024
Cited by: 0 articles | PMID: 39392550
Add to export list
Physician Perspectives on the Management of Patients with Resected High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck Who Are Ineligible to Receive Cisplatin: A Podcast.
Haddad RI, Harrington K
Target Oncol, 19(6):823-832, 15 Oct 2024
Cited by: 0 articles | PMID: 39405014 | PMCID: PMC11557660
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Single-Hit and Multi-hit PIK3CA Short Variant Genomic Alterations in Clinically Advanced Prostate Cancer: A Genomic Landscape Study.
Basin MF, Miguel CM, Jacob JM, Goldberg H, Grivas P, Spiess PE, Necchi A, Kamat AM, Pavlick DC, Huang RSP, Lin DI, Danziger N, Sokol ES, Sivakumar S, Graf R, Cheng L, Vasan N, Ross J, Basnet A, Bratslavsky G
Target Oncol, 19(6):981-990, 05 Oct 2024
Cited by: 0 articles | PMID: 39369133 | PMCID: PMC11557715
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Impact of Etiology on Efficacy Outcomes with Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Retrospective Analysis in Asia-Pacific.
Kim S, Lee SY, Cheon J, Kim HD, Park YG, Lee JJX, Ryu MH, Ryoo BY, Tai D, Yoo C
Target Oncol, 19(6):917-923, 03 Oct 2024
Cited by: 0 articles | PMID: 39361219
Add to export list
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2<sup>EV</sup> Study.
Fiala O, Massari F, Basso U, Giannatempo P, Grande E, Buti S, Myint ZW, De Giorgi U, Pichler R, Grillone F, Ürün Y, Calabrò F, Bourlon MT, Galli L, Kanesvaran R, Roviello G, Kucharz J, Rizzo M, Park SH, [...] Santoni M
Target Oncol, 19(6):905-915, 01 Oct 2024
Cited by: 0 articles | PMID: 39354179 | PMCID: PMC11557677
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Real-Life Experience with Entrectinib in Neurotrophic Tyrosine Receptor Kinase Fusion-Positive Solid Tumors: A Multicenter Retrospective Trial.
Yılmaz F, Yaşar S, Mandel NM, Kaçan T, Özdemir M, Doğu GG, Şengül N, Meydan N, Başal FB, Tolunay PK, Hamamcı MB, Dinçer OS, Bahçeci A, Özer L, Ajredini M, Kırca Ö, Yersal Ö, Can O, Günaldı M, [...] Yalçın Ş
Target Oncol, 19(6):957-964, 25 Sep 2024
Cited by: 0 articles | PMID: 39317891
Add to export list
Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01.
Hibino M, Imamura Y, Shimoyama R, Fukui T, Fukai R, Iwase A, Tamura Y, Chihara Y, Okabe T, Uryu K, Okuda T, Taguri M, Minami H
Target Oncol, 19(6):925-939, 20 Sep 2024
Cited by: 0 articles | PMID: 39302602 | PMCID: PMC11557658
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Evaluation of Drug-Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model.
Willemin ME, Gong J, Hilder BW, Masterson T, Tolbert J, Renaud T, Heuck C, Kane C, De Zwart L, Girgis S, Ma X, Ouellet D
Target Oncol, 19(6):965-979, 16 Sep 2024
Cited by: 0 articles | PMID: 39285155 | PMCID: PMC11557650
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
The Epidemiology of Biliary Tract Cancer and Associated Prevalence of MDM2 Amplification: A Targeted Literature Review.
Kratz JD, Klein AB, Gray CB, Märten A, Vilu HL, Knight JF, Kumichel A, Ueno M
Target Oncol, 19(6):833-844, 20 Sep 2024
Cited by: 0 articles | PMID: 39302603 | PMCID: PMC11557622
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics.
Wu LW, Jang SJ, Shapiro C, Fazlollahi L, Wang TC, Ryeom SW, Moy RH
Target Oncol, 19(6):845-865, 13 Sep 2024
Cited by: 0 articles | PMID: 39271577 | PMCID: PMC11557641
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1).
Santini D, Li H, Roviello G, Park SH, Grande E, Kucharz J, Basso U, Fiala O, Monteiro FSM, Poprach A, Buti S, Molina-Cerrillo J, Catalano M, Buchler T, Seront E, Ansari J, Myint ZW, Ghosn M, Calabrò F, [...] Santoni M
Target Oncol, 19(6):893-903, 17 Sep 2024
Cited by: 0 articles | PMID: 39289313
Add to export list
Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.
Sho T, Suda G, Ohara M, Kohya R, Sasaki T, Yoshida S, Hosoda S, Ogawa K, Kitagataya T, Maehara O, Ohnishi S, Kawagishi N, Natsuizaka M, Nakai M, Baba M, Yamamoto Y, Tsukuda Y, Meguro T, Yamada R, [...] NORTE STUDY GROUP
Target Oncol, 19(5):769-778, 02 Sep 2024
Cited by: 0 articles | PMID: 39222223
Add to export list
A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma.
Gong J, Guo Y, Zhang Y, Ba Y, Chen T, Li W, Zhou C, Wang M, Yang H, Zhou Y, Cai Q, Wang Z, Huang G, Zhang W, Su R, Cai Z, Yue Z, Dou J, Li P, [...] Shen L
Target Oncol, 19(5):723-733, 04 Sep 2024
Cited by: 0 articles | PMID: 39231855
Add to export list
Correction to: Moving T‑Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review.
Fowler NH, Chavez JC, Riedell PA
Target Oncol, 19(5):817, 01 Sep 2024
Cited by: 0 articles | PMID: 39028410 | PMCID: PMC11392971
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
lnsights into Adjuvant Systemic Treatment Selection for Patients with Stage III Melanoma: Data from the Dutch Cancer Registry.
Aldenhoven L, van Weezelenburg MAS, van den Berkmortel FWPJ, Servaas N, Janssen A, Vissers YLJ, van Haaren ERM, Beets GL, van Bastelaar J
Target Oncol, 19(5):735-745, 24 Aug 2024
Cited by: 0 articles | PMID: 39182000 | PMCID: PMC11393025
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

1-25 of 985 results

1 2 3 Next ...

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

Partnerships & funding